We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Regeneron Pharmaceuticals (REGN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Regeneron Pharmaceuticals is a member of our Medical group, which includes 756 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. REGN is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for REGN's full-year earnings has moved 12.79% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, REGN has returned 4.14% so far this year. At the same time, Medical stocks have gained an average of 11.06%. As we can see, Regeneron Pharmaceuticals is performing better than its sector in the calendar year.
Looking more specifically, REGN belongs to the Medical - Biomedical and Genetics industry, which includes 280 individual stocks and currently sits at #108 in the Zacks Industry Rank. On average, stocks in this group have gained 1.40% this year, meaning that REGN is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to REGN as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Regeneron Pharmaceuticals (REGN - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Regeneron Pharmaceuticals is a member of our Medical group, which includes 756 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. REGN is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for REGN's full-year earnings has moved 12.79% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, REGN has returned 4.14% so far this year. At the same time, Medical stocks have gained an average of 11.06%. As we can see, Regeneron Pharmaceuticals is performing better than its sector in the calendar year.
Looking more specifically, REGN belongs to the Medical - Biomedical and Genetics industry, which includes 280 individual stocks and currently sits at #108 in the Zacks Industry Rank. On average, stocks in this group have gained 1.40% this year, meaning that REGN is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to REGN as it looks to continue its solid performance.